ArticleScientific reports2025
Design and evaluation of octopromycin-derived peptides as multifunctional antimicrobial agents against multidrug-resistant pathogens.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Octopromycin (OPM), an antimicrobial peptide from Octopus minor, shows potent activity against multidrug-resistant (MDR) Acinetobacter baumannii. Guided by the structure-activity relationship of the N-terminal domain OPM23, we designed short α-helical peptides with enhanced antimicrobial, anti-inflammatory, and antibiofilm properties while maintaining low toxicity. Antimicrobial activity was assessed by broth microdilution; protease and serum stability by HPLC. Mechanism of action was examined using membrane depolarization, NPN uptake, β-galactosidase (ONPG) hydrolysis, flow cytometry, and scanning electron microscopy. Anti-inflammatory effects were evaluated by ELISA, RT-PCR, and lipopolysaccharide (LPS) interaction assays, and biofilm inhibition/eradication was tested against MDR Pseudomonas aeruginosa (MDRPA). Four peptides-OPM23-a7, OPM23-a8, and their D-enantiomers OPM23-a7-d and OPM23-a8-d-exhibited strong antimicrobial, anti-inflammatory, and antibiofilm activities with minimal hemolytic and cytotoxic effects. The D-enantiomers showed pronounced stability under physiologically challenging conditions, including high salt, proteolytic environments, and human serum. Mechanistic studies indicated disruption of bacterial membrane integrity with leakage of intracellular contents. In LPS-stimulated RAW264.7 macrophages, the peptides suppressed pro-inflammatory cytokine release via dual actions-direct LPS binding and inhibition of LPS-receptor interactions. Beyond preventing MDRPA biofilm formation, the peptides substantially reduced biomass and viability within mature biofilms. Collectively, the OPM-derived peptides showed multifunctional activity in vitro with favorable stability and low toxicity. These findings support their potential as promising peptide candidates, while in vivo efficacy and pharmacokinetic studies will be required to assess translational feasibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.